Improved clinical benefit with Lapatinib plus Capecitabine in HER2+ metastatic Breast Cancer

ABSTRACT

Background: Lapatinib is a dual tyrosine kinase inhibitor blocking human epidermal growth factor receptors [HER1, HER2]. Lapatinib in combination with Capecitabine has showed efficacy in HER2+ metastatic breast cancer [MBC] previously treated with Anthracycline, Taxane and Trastuzumab. This study is the first to evaluate the clinical benefit and safety of the combination of Lapatinib and Capecitabine in HER2+ MBC previously treated with Anthracycline, Taxane and Trastuzumab, treated at Albairouni Cancer Center